SCHEMBL4036050

SCHEMBL4036050

C=CCSC(SCC=C)=C1C(=O)c2ccccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.41
LMNA P02545 4/20 0.40
TDP2 O95551 4/20 0.40
ALDH1A1 P00352 4/20 0.40
MAPT P10636 4/20 0.40
HTT P42858 3/20 0.40
S100A4 P26447 3/20 0.40
PLA2G1B P04054 3/20 0.40
ATG4B Q9Y4P1 3/20 0.40
NSD2 O96028 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HSP90AA1 P07900 1/20 0.40
CCR6 P51684 1/20 0.40
ALOX15 P16050 1/20 0.40
PKM P14618 1/20 0.39
KMT2A Q03164 5/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
PTPRC P08575 2/20 0.38
MITF O75030 1/20 0.38
SENP8 Q96LD8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30423947 0.70 CDC25B (0.54) LMNATDP2ALDH1A1MAPTHTT
SCHEMBL6481220 0.70 CDC25B (0.54) LMNATDP2ALDH1A1MAPTHTT
SCHEMBL6793063 0.67 MEN1 (0.33) LMNAKMT2AMEN1
Anthraquinone SCHEMBL8517968 0.66 KMT2A (0.57) CASP3LMNATDP2ALDH1A1MAPT
SCHEMBL4784115 0.66 PTPRC (0.50) LMNAALDH1A1MAPTS100A4NSD2
SCHEMBL8942748 0.65 CASP3 (0.48) CASP3LMNATDP2ALDH1A1MAPT
SCHEMBL8423601 0.64 AKT1 (0.47) LMNAALDH1A1MAPTALOX15KMT2A
SCHEMBL5056798 0.63 CYP2C19 (0.46) LMNAALDH1A1MAPTHTTPKM
Anthraquinone SCHEMBL10663875 0.63 PTPRC (0.56) CASP3LMNATDP2ALDH1A1MAPT
Anthraquinone SCHEMBL11789994 0.63 KMT2A (0.56) CASP3LMNATDP2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1673354-B1 ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS ORTHO MCNEIL PHARM INC (US) 2009-04-22 EP disclosed